FDA OKs Lung Cancer Rx Portrazza
The U.S. Food and Drug Administration today approved Portrazza (necitumumab) in combination with two forms of chemotherapy to treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC) who have not previously received medication specifically for treating their advanced lung cancer.
FDA Approves New Lung Cancer Rx
On November 13, 2015, the U. S. Food and Drug Administration granted accelerated approval to osimertinib (TAGRISSO) once daily tablets, AstraZeneca Pharmaceuticals LP, for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy.
FDA Expands Opdivo Approval
The U.S. Food and Drug Administration today approved Opdivo (nivolumab) to treat patients with advanced (metastatic) non-small cell lung cancer whose disease progressed during or after platinum-based chemotherapy.
Melanoma Rx May Treat Lung Cancer, Too
Turns out a melanoma medication could also help patients with a different type of cancer.
Advanced Non-Small Cell Lung Cancer Rx Approved
The U.S. Food and Drug Administration today granted accelerated approval for Keytruda (pembrolizumab) to treat patients with advanced (metastatic) non-small cell lung cancer (NSCLC) whose disease has progressed after other treatments and with tumors that express a protein called PD-L1. Keytruda is approved for use with a companion diagnostic, the PD-L1 IHC 22C3 pharmDx test, the first test designed to detect PD-L1 expression in non-small cell lung tumors.
New Guidelines for Smokers' Health Care
Smoking has been tied to numerous health issues. Now an expert panel has made recommendations for doctors who care for adults and pregnant women who smoke.
How Ethnicity Affects Cancer Risk
Your ethnicity may be a factor in your cancer risk.
How to Quit Smoking
You’ve decided to kick the habit? That’s great! Read on to learn your options and prepare yourself before you pitch your last pack — it could make all the difference in your success!
FDA Approves Targeted Rx for Lung Cancer
The U.S. Food and Drug Administration today approved Iressa (gefitinib) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors harbor specific types of epidermal growth factor receptor (EGFR) gene mutations, as detected by an FDA-approved test.
Living up to Your Potential Life Span
No one lives forever. But you may be able to increase your life span.